DifGen Wins FDA IND Clearance for Breast Cancer Therapy
Miramar, Fla., July 27, 2026 DifGen Pharmaceuticals LLC has announced that the U.S. Food and Drug Administration (FDA) has...
Mesothelioma
Advertisement
Insilico Medicine Presents ISM6331 Phase 1 Data at ESMO
Cambridge, MA, July 27, 2026 Insilico Medicine has announced that first-in-human Phase 1 clinical trial data for ISM6331, its...
Orion Pharma Presents First ODM-212 Cancer Trial Data at ASCO 2026
ESPOO, Finland, May 21, 2026 Orion Pharma announced that it will present the first clinical data from its ongoing...
Vivace Therapeutics Gains FDA Fast Track Designation for VT3989 in Mesothelioma
SAN MATEO, Calif., October 8, 2025 — Vivace Therapeutics, Inc., a biotechnology company pioneering small molecule cancer therapies that...
Advertisement
